Skip to main content
TipRanks
Go Ultimate75% OFF

Alvotech (Z45) Stock Price & Analysis

0 Followers

Z45 Stock Chart & Stats

€3.96€0.34(9.39%)
At close: 5:30 PM GMT+1
€3€3.5€4€4.5Jul 6Jul 8Aug 11Aug 24Sep 11Sep 28
Day’s Range
EUR 3.86 - EUR 3.96
52-Week Range
EUR 2.52 - EUR 5.38
Previous Close
EUR 3.62
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 1.42B
Enterprise Value
EUR 3.57B
Total Cash (Recent Filing)
EUR 61.47M
Total Debt (Recent Filing)
EUR 1.56B
Price to Earnings (P/E)
―
Beta
0.58
Next Earnings
Mar 10, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Commercial Performance

The sharp increase in product revenue and adjusted EBITDA indicates improving commercial traction as established products and newer launches gain reach. If sustained, stronger product-led performance can reduce reliance on licensing timing and support better operating leverage over coming quarters.

Manufacturing Productivity

Higher output per batch allows Alvotech to produce equivalent volumes with fewer production runs, improving use of existing infrastructure and freeing capacity for additional biosimilars. This can strengthen supply reliability, support partner demand, and improve manufacturing economics over time.

Pipeline And Commercial Expansion

The Lotus partnership broadens Alvotech's pipeline exposure across oncology and rare-disease biosimilars while expanding geographic access. Potential milestone payments, supply revenue, and direct U.S. participation could diversify commercialization economics and increase the value captured from future launches.

Bears Say

High Leverage And Negative Equity

The combination of substantial debt and negative equity leaves Alvotech with limited financial flexibility. Leverage raises refinancing and interest burdens, constrains investment choices, and increases the consequences of operational delays or weaker product launches during the next several quarters.

Persistent Cash Burn

Recurring operating and free-cash-flow deficits mean the business has not yet funded its development and manufacturing needs internally. Continued cash burn increases dependence on external financing and makes the balance-sheet burden more material until management's expected cash-flow improvement is achieved.

Revenue And Margin Volatility

Declining revenue and compressed product margins demonstrate that scale has not yet translated into stable earnings power. Revenue timing, manufacturing recovery, and mix effects can continue to create volatility, making near-term profitability and cash generation less dependable despite pipeline progress.

Alvotech News

Z45 FAQ

What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was €2.52 and its highest was €5.38 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is €1.42B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s next earnings report is estimated for Mar 10, 2027 (not yet confirmed), which is in 112 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on Nov 11, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of -€0.027 by -€0.009.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is 0.15.
How many shares outstanding does Alvotech have?
Alvotech has 356,817,050 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -€0.036 in its last earnings report, missing expectations of -€0.027. Following the earnings report the stock price went down -8.447%.
Which hedge fund is a major shareholder of Alvotech?
Hedge funds hold Alvotech shares: the largest hedge-fund position in Alvotech is 667,651,398 shares, and hedge funds increased their holdings by 3.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology